Precision‑health adoption warning
A physician active in genomics warned on X that the path from discovery to clinical prevention often follows 'Discovery → Resistance → Delay', arguing that implementation must catch up with innovation. The post links the critique to an upcoming Precision Health Summit and urges more focus on putting genomic tools into practice. (x.com)
Precision health aims to match prevention and treatment to a person’s biology, and one genomics physician says the hard part is no longer discovery but getting tools into care. (x.com) In a post on X, Dr. Anmol Kapoor wrote that medicine often moves from “Discovery” to “Resistance” to “Delay,” then tied that complaint to an upcoming Precision Health and Longevity Summit in Calgary on April 25-26, 2026. (x.com) (precisionlongevitysummit.com) Kapoor is a Canadian cardiologist who has publicly argued for wider use of genomics, artificial intelligence, and preventive screening in routine care. His summit says it will focus on practical, scalable precision-health tools rather than research alone. (drishtimagazine.com) (precisionlongevitysummit.com) Genomics is the reading of DNA, the body’s instruction code, to spot inherited disease risk before symptoms appear. United States public-health agencies already treat some uses as ready for action, including testing pathways tied to hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia. (archive.cdc.gov) The Centers for Disease Control and Prevention says nearly 2 million people in the United States may carry one of those three high-impact inherited conditions, and many do not know it. The agency says early detection and intervention can cut illness and death, but the healthcare system still misses many families. (archive.cdc.gov 1) (archive.cdc.gov 2) That gap between what science can identify and what clinics routinely deliver has become a policy issue as sequencing gets cheaper and faster. The National Academies has framed the current task as integrating genomics into health-care practice across the full continuum of precision health care. (ncbi.nlm.nih.gov) (sciencedirect.com) Federal and academic groups are now testing that handoff in newborns, one of the clearest examples of moving from lab insight to prevention. The National Institutes of Health-backed BEACONS program says it plans to enroll up to 30,000 newborns in as many as 10 states to study whether genome sequencing can be added responsibly to public-health screening. (beaconsnbs.org) (massgeneralbrigham.org) Not everyone wants faster rollout without guardrails. Reviews of genomic newborn screening say the promise of earlier detection comes with unresolved questions on consent, privacy, equity, and which findings should be returned to families. (pmc.ncbi.nlm.nih.gov) Kapoor’s post lands as precision-medicine conferences increasingly put “implementation” in the program, not just discovery. Nature’s 2026 precision-medicine meeting says its agenda runs from validation to implementation and policy, a sign that the bottleneck he described is now a central theme across the field. (precision-medicine.conferences.nature.com) The argument in Kapoor’s thread was simple: genomics already has uses that can prevent disease, and the next fight is whether health systems adopt them faster than they postpone them. (x.com)
